MDT

MDT

USD

Medtronic plc. Ordinary Shares

$84.160-0.250 (-0.296%)

Precio en Tiempo Real

Healthcare
Dispositivos médicos
Irlanda

Gráfico de Precios

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$84.410

Máximo

$84.660

Mínimo

$83.500

Volumen

0.71M

Fundamentos de la Empresa

Capitalización de Mercado

108.1B

Industria

Dispositivos médicos

País

Ireland

Estadísticas de Negociación

Volumen Promedio

7.62M

Bolsa

NYQ

Moneda

USD

Rango de 52 Semanas

Mínimo $75.96Actual $84.160Máximo $96.25

Informe de Análisis de IA

Última actualización: 27 abr 2025
Generado por IAFuente de Datos: Yahoo Finance, Bloomberg, SEC

MDT: Medtronic plc. Ordinary Shares - What's Happening and What to Watch

Stock Symbol: MDT Generate Date: 2025-04-27 07:55:19

Alright, let's take a look at what's been going on with Medtronic lately. Think of this as a quick chat about the stock, cutting through the noise to see what matters.

The Latest Buzz (News Sentiment)

So, what's the general feeling around Medtronic based on the recent news? Mostly, it sounds pretty positive on the product front. We've seen a bunch of announcements about new medical devices getting the green light from the FDA or showing good results in trials.

  • They've got promising data for their tech that treats atrial fibrillation (a heart rhythm issue).
  • Their robotic surgery system, Hugo, hit its safety and effectiveness goals in a trial.
  • A new, smaller defibrillator lead got FDA approval.
  • And a new sensor for their MiniMed insulin pump system also got the FDA nod.

These are all good signs. It means the company is innovating and getting new products ready for market, which is crucial for a medical device giant.

On the flip side, there was one analyst from Truist Securities who lowered their price target slightly, from $93 to $90, while keeping a "Hold" rating. That's a small negative note, suggesting they see less potential upside in the near term than before.

Overall, the news flow is heavily tilted towards positive developments for their core business – new and improved medical tech.

Checking the Price Tag (Price Action & AI Prediction)

Now, let's look at what the stock price itself has been doing over the last month or so. It's been a bit of a bumpy ride.

Back in late January and early February, the stock was hanging out mostly in the $90-$92 range. Then, it took a noticeable dip around mid-February before bouncing back up into the low $90s by early March.

But since early March, the trend has been pointing downwards. We saw a pretty sharp drop in early April, pushing the price down into the low $80s. The last price we have data for (April 25th) was $84.16. So, compared to where it was a couple of months ago, the stock has definitely lost ground.

What about the crystal ball? The AI prediction model gives us a mixed short-term view. It expects a tiny uptick today (+0.16%) and tomorrow (+0.12%), basically staying flat. But then, it predicts a more significant drop the day after (-2.26%). This suggests the recent downward pressure might not be entirely over just yet, according to the model.

What Does It All Mean? (Outlook & Strategy Ideas)

Putting the news and the price action together, we get a somewhat conflicting picture. The company is clearly doing good things with its products – getting approvals, showing positive trial results. That's fundamentally positive for the long run.

However, the stock price has been moving in the opposite direction lately, trending down, and the AI prediction hints at more potential weakness just ahead. This tells us that despite the good news, other factors (maybe broader market conditions, investor sentiment towards the sector, or those fundamental concerns like lower growth and higher debt mentioned in some analysis) are currently weighing on the stock.

Given this mix, the situation seems to lean towards a cautious approach right now. It's probably not a screaming "buy" signal when the price trend is down and an AI predicts a dip. It's also not necessarily a clear "sell" if you believe the positive product news will eventually turn things around. A "hold" or "wait and see" might be the most sensible stance for many.

  • Potential Entry Consideration: If you're interested in Medtronic because of the positive product pipeline, waiting might be smart. The AI predicts a dip after the next couple of days. Maybe watch to see if the stock price stabilizes after that predicted dip, or if it shows a clear sign of reversing its recent downtrend. Some analysis points to support around $84.03 (very close to the last price) and $83.88 - $84.14 as potential entry areas, but given the predicted dip, confirming support holds after any potential drop seems prudent.
  • Potential Exit/Stop-Loss Consideration: If you currently hold the stock, or if you decide to enter and the price continues to fall, managing your risk is key. Some analysis suggests a stop-loss level around $81.84. This is below the recent lows we saw in early April. If the price drops below that level, it could signal that the downtrend is accelerating, and cutting losses might be a strategy to consider. For taking profits, a level like $85.81 has been mentioned, but hitting that might depend on the stock reversing its recent direction.

Quick Company Snapshot

Just to keep things in perspective, Medtronic is a massive player in the medical device world. They make all sorts of crucial health tech, from pacemakers to surgical robots to insulin pumps. The recent news about specific device approvals is right in their wheelhouse and directly impacts their ability to sell products. However, like any big company, they face challenges, including managing growth and debt, which some analysis highlights.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

Noticias Relacionadas

PR Newswire

Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial...

Ver más
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients
PR Newswire

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical...

Ver más
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system
PR Newswire

Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™...

Ver más
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results
GlobeNewswire

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in

Ver más
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
PR Newswire

New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the...

Ver más
New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved
GlobeNewswire

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

PALM BEACH, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial intelligence (AI) is being utilized for disease detection in the global markets. In today's AI-driven world, the use of

Analyst Upgrades

Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $90

Truist Securities analyst Richard Newitter maintains Medtronic with a Hold and lowers the price target from $93 to $90.

Predicción de IABeta

Recomendación de IA

Bajista

Actualizado el: 27 abr 2025, 22:38

BajistaNeutralAlcista

63.5% Confianza

Riesgo y Negociación

Nivel de Riesgo1/5
Riesgo Bajo
Adecuado Para
Conservador
Guía de Negociación

Punto de Entrada

$83.88

Toma de Ganancias

$85.81

Stop Loss

$81.84

Factores Clave

PDI 3.9 está por encima de MDI 3.0 con ADX 10.2, lo que sugiere una tendencia alcista
El precio actual está extremadamente cerca del nivel de soporte ($84.03), lo que sugiere una fuerte oportunidad de compra
El volumen de operaciones es 6.0 veces el promedio (77,889), lo que indica una presión de compra extremadamente fuerte
El MACD -0.0136 está por encima de la línea de señal -0.0145, lo que indica un cruce alcista

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.